Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine. 2002

Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
Department of Human Retrovirology, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. b.berkhout@amc.uva.nl

Despite intensive efforts, no safe and effective vaccine has been developed for the prophylaxis of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Studies with the simian immunodeficiency virus (SIV)/macaque model demonstrated that live attenuated viruses are the most effective vaccines tested thus far. However, due to ongoing low-level replication of the attenuated virus and the error-prone replication machinery, the attenuated virus may regain replication capacity and become pathogenic. We therefore designed a novel vaccine strategy with an HIV-1 virus that replicates exclusively in the presence of the nontoxic effector doxycycline (dox). This was achieved by replacement of the viral TAR-Tat system for transcriptional activation by the Escherichia coli-derived Tet system for inducible gene expression. This designer HIV-rtTA virus replicates in a strictly dox-dependent manner and may represent an improved vaccine strain because its replication can be turned on and off at will. Spontaneous virus evolution resulted in optimization of the components of the Tet system for their new function to support virus replication in human cells. The optimised Tet system may be of particular use in other applications such as inducible expression of gene therapy vectors in the brain.

UI MeSH Term Description Entries
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D016915 AIDS Vaccines Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced. AIDS Vaccine,HIV Vaccine,HIV Vaccines,Vaccine, AIDS,Vaccine, HIV

Related Publications

Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
October 2002, Expert review of vaccines,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
March 2018, Nature communications,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
February 2016, Virology,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
May 1964, Nature,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
May 1997, Cleveland Clinic journal of medicine,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
September 2008, The Journal of general virology,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
January 1997, Nature medicine,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
January 1983, Developments in biological standardization,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
July 1989, Avian pathology : journal of the W.V.P.A,
Ben Berkhout, and Koen Verhoef, and Giuseppe Marzio, and Bep Klaver, and Monique Vink, and Xue Zhou, and Atze T Das
February 1968, The New England journal of medicine,
Copied contents to your clipboard!